ProQR Q3 Loss Widens - Quick Facts

(RTTNews) - ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, reported a third-quarter net loss of 3.4 million euros or 0.43 euros per share, compared to a loss of 0.9 million euros or 0.14 euros per share for the same period in 2013.

Net cash generated by financing activities during the three months ended September 30, 2014 was 80.2 million euros. Research and development costs were 2.5 million euros for the period, compared to 0.7 million euros, a year ago.